Journal of Cancer Therapy

Volume 5, Issue 6 (May 2014)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.52  Citations  h5-index & Ranking

ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer

HTML  Download Download as PDF (Size: 347KB)  PP. 483-492  
DOI: 10.4236/jct.2014.56055    3,510 Downloads   4,550 Views   Citations


The Epidermal Growth Factor system is present in human organs and plays an important role in cell proliferation, differentiation and apoptosis during embryogenesis and postnatal development. It has four receptors (EGFR, ErbB-2, ErbB-3 and ErbB-4) and numerous ligands. Dysregulation of the Epidermal Growth Factor signaling network is implicated in the pathogenesis of various disorders. Especially in cancer, the Epidermal Growth Factor system becomes hyperactivated with various mechanisms (ligand overproduction, receptor overproduction, constitutive receptor activation). EGFR overexpression may have a dual role in endometrial cancer. It seems that in type I endometrial cancer, EGFR overexpression did not affect disease progression. However in type II endometrial cancer, EGFR overexpression associated with high grade disease and adverse clinical outcome. Moreover ΕrbB-2 overexpression especially in type II endometrial cancer, is an indicator of a highly aggressive disease with poor overall survival. The potential role of ErbB receptors (especially EGFR and ErbB-2) as targets for cancer therapy has been investigated for over 20 years. There are 2 major classes of ErbB targeted therapies: anti-ErbB monoclonal antibodies (MoAbs) and ErbB-specific tyrosine kinase inhibitors (TKIs). ErbB targeted therapies have still shown modest effect in unselected endometrial cancer patients. However, they may be clinically active as adjuvant therapy in well-defined subgroups of type II endometrial cancer patients with EGFR and ErbB-2 overexpression.

Cite this paper

Androutsopoulos, G. , Michail, G. , Adonakis, G. and Decavalas, G. (2014) ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer. Journal of Cancer Therapy, 5, 483-492. doi: 10.4236/jct.2014.56055.

Cited by

[1] Systems for the delivery of chemotherapeutic drugs, new approaches and perspective
Russian Open Medical Journal, 2017
[2] Standard and novel therapies in endometrial cancer
[3] New insights in endometrial cancer treatment
[4] Endometrial cancer treatment: ne w insights into the role of erbb receptors
[5] Endometrial Cancer Treatment: New Insights into the Role of Erbb Receptors
[6] Molecular Mechanisms, Expression and Clinical Role of Erbb Re-ceptors in Endometrial Cancer
Int J Clin Ther Diagn. S, 2015
[7] Current Treatment Approach of Endometrial Cancer
Int J Clin Ther Diagn. S, 2015
[8] Present and Future in Endometrial Cancer Treatment
Obstet Gynecol Int J, 2015
[9] Endometrial Cancer-Diagnosis
Int J Clin Ther Diagn. S, 2015
[10] ErbB targeted therapy in endometrial cancer
Int J Clin Ther Diagn. S, 2015
[11] Molecular biology, expression and clinical significance of ErbB receptors in endometrial cancer
HJOG, 2014

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.